BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31482523)

  • 21. BRAF(V600E) mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma.
    Jing FJ; Liang J; Liang ZY; Meng C; Long W; Li XY; Lin YS
    Chin Med J (Engl); 2013 Aug; 126(16):3013-8. PubMed ID: 23981603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
    Routhier CA; Mochel MC; Lynch K; Dias-Santagata D; Louis DN; Hoang MP
    Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.
    Callebout E; Ribeiro SM; Laurent S; De Man M; Ferdinande L; Claes KBM; Van der Meulen J; Geboes KP
    BMC Cancer; 2019 Jun; 19(1):567. PubMed ID: 31185985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic value of fine needle aspiration BRAF(V600E) mutation analysis in papillary thyroid cancer: a systematic review and meta-analysis.
    Fnais N; Soobiah C; Al-Qahtani K; Hamid JS; Perrier L; Straus SE; Tricco AC
    Hum Pathol; 2015 Oct; 46(10):1443-54. PubMed ID: 26232865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
    Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
    Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the Clinical Usefulness of BRAFV600E Mutation Analysis of Core-Needle Biopsy Specimens in Thyroid Nodules with Previous Atypia of Undetermined Significance or Follicular Lesions of Undetermined Significance Results.
    Choi SH; Baek JH; Lee JH; Choi YJ; Song DE; Chung KW; Kim TY; Shong YK
    Thyroid; 2015 Aug; 25(8):897-903. PubMed ID: 25978151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.
    Zhao H; Zhang ZH; Zhou B; Xiao T; Pan QJ; Guo HQ
    Diagn Cytopathol; 2015 Oct; 43(10):786-90. PubMed ID: 26152656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic value of BRAF(V600E) mutation analysis of thyroid nodules according to ultrasonographic features and the time of aspiration.
    Moon HJ; Kim EK; Chung WY; Choi JR; Yoon JH; Kwak JY
    Ann Surg Oncol; 2011 Mar; 18(3):792-9. PubMed ID: 20945104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conventional Ultrasound, Immunohistochemical Factors and BRAF
    Chen J; Li XL; Zhao CK; Wang D; Wang Q; Li MX; Wei Q; Ji G; Xu HX
    Ultrasound Med Biol; 2018 Nov; 44(11):2296-2306. PubMed ID: 30100099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
    Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L
    Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Correlation between Ultrasound-guided Fine-needle Aspiration Combined with BRAF
    Zhang Y; Luo YK; Zhang Y; Zhang MB; Guang Y; Xie F; Jiang B; Tang J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Aug; 41(4):517-523. PubMed ID: 31484615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dabrafenib plus trametinib in patients with previously untreated BRAF
    Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
    Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Critical Pitfalls in the use of BRAF Mutation as a Diagnostic Tool in Thyroid Nodules: a Case Report.
    Kuhn E; Ragazzi M; Zini M; Giordano D; Nicoli D; Piana S
    Endocr Pathol; 2016 Sep; 27(3):220-3. PubMed ID: 26782803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome.
    Thomsen M; Skovlund E; Sorbye H; Bolstad N; Nustad KJ; Glimelius B; Pfeiffer P; Kure EH; Johansen JS; Tveit KM; Christoffersen T; Guren TK
    Br J Cancer; 2018 Jun; 118(12):1609-1616. PubMed ID: 29872151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
    Huang M; Yan C; Xiao J; Wang T; Ling R
    Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.
    Gawlick U; Lu KC; Douthit MA; Diggs BS; Schuff KG; Herzig DO; Tsikitis VL
    Am J Surg; 2013 May; 205(5):608-12; discussion 612. PubMed ID: 23592171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status.
    Kim SK; Hwang TS; Yoo YB; Han HS; Kim DL; Song KH; Lim SD; Kim WS; Paik NS
    J Clin Endocrinol Metab; 2011 Mar; 96(3):658-64. PubMed ID: 21239517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytomorphologic features in thyroid nodules read as "suspicious for malignancy" on cytology may predict thyroid cancers with the BRAF mutation.
    Kwon HJ; Kim EK; Kwak JY
    Pathol Res Pract; 2015 Sep; 211(9):671-6. PubMed ID: 26187369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.